Browse > Home / Actoplus / Roche discloses the results of first Phase III clinical study using Taspoglutide

Roche discloses the results of first Phase III clinical study using Taspoglutide

October 28, 2009

Ipsen (Paris:IPN), an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of a first phase III clinical study using Taspoglutide, the first human formerly weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s Research. Results from Roche’s Phase III scrutinize T-EMERGE 2 met its primary endpoint of make different in HbA1c (subcutaneous weekly taspoglutide versus subcutaneous twice-daily exenatide, as add-on to metformin, a thiazolidinedione [TZD], or metformin and a TZD). A superiority versus exenatide was demonstrated.

This hotch-potch is similar to the natural hormone GLP-1 that has a key role in blood flatter regulation. GLP-1 analogues, which inflame insulin secretion and hush up glucagon secretion, are constant innovations in the diabetes field.

The results showed that taspoglutide demonstrated greater HbA1c reduction versus exenatide following 24 weeks of treatment. The study analysis included 1,189 patients, equally randomized into three active deeds of arms (taspoglutide 10 mg once weekly, taspoglutide 10 mg once weekly titrated up to 20 mg formerly weekly after 4 weeks, and exenatide 10 mcg two times quotidian). Taspoglutide was generally well tolerated. The in the greatest degree often reported conflicting events amid taspoglutide and exenatide treated patients were nausea and vomiting.

http://www.ipsen.com/

Written by Samanta · Filed Under Actoplus